The cost effectiveness agency for England and Wales said that it would not recommend abiraterone, a drug considered to be a breakthrough second-line treatment for men with castration-resistant metastatic prostate cancer.The National Institute for Health and Clinical Excellence said that abiterone's cost was the main factor bearing on its negative draft guidance, which is now subject to public and manufacturer consultation. NICE indicated that it would be open to considering the drug if its manufacturer...